CNS Spectr. 2014 Jun;19(3):207-12. doi: 10.1017/S1092852914000248.
A striking and unexpected pharmacologic synergy has been shown between antagonist actions at serotonergic 5HT2C receptors, and agonist actions at melatonergic receptors by agomelatine, a drug that has both of these properties.
阿戈美拉汀具有 5-羟色胺 2C 受体拮抗剂和褪黑素受体激动剂双重特性,它在发挥这两种作用的同时,表现出一种显著而又出人意料的药物协同作用。